| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 06/26/2002 | CN1086585C Medicine for pulmonary diseases and its preparation method |
| 06/26/2002 | CN1086582C Anal fissure ointment and its preparing process |
| 06/26/2002 | CN1086580C Antipruritic ointment for dermatitis |
| 06/26/2002 | CN1086579C Oral formulations of antifungal |
| 06/26/2002 | CN1086575C New stable medicinal compositions for generating propellant-free aerosols |
| 06/26/2002 | CN1086568C Health-care tea/drink of traditional chinese herbs |
| 06/25/2002 | US6410789 Using heterogeneity mixed oxide catalyst |
| 06/25/2002 | US6410782 Bioavailability; side effect reduction; mixture with an aminoalcohol |
| 06/25/2002 | US6410645 Multiblock biodegradable hydrogels for drug delivery and tissue treatment |
| 06/25/2002 | US6410601 Histochrome and its therapeutic use in acute myocardial infarction and ischemic heart disease |
| 06/25/2002 | US6410599 Mixture of benzalkonium chloride, water and isopropanol |
| 06/25/2002 | US6410595 Methods and compositions for treating male erectile dysfunction |
| 06/25/2002 | US6410590 Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| 06/25/2002 | US6410579 Use of pramipexole for the treatment of addictive disorders |
| 06/25/2002 | US6410575 Administering (5-aryl-1,2,4-thiadiazol)-3-yl thiourea and urea derivatives to treat hepatitis, hiv and kaposi sarcoma, as viricides and anticarcinogenic agents |
| 06/25/2002 | US6410517 Targeted gene delivery system |
| 06/25/2002 | US6410511 Formulations for amylin agonist peptides |
| 06/25/2002 | US6410328 Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
| 06/25/2002 | US6410218 Plasma-like solution |
| 06/25/2002 | US6410061 Tea catechins as cancer specific proliferation inhibitors |
| 06/25/2002 | US6410057 Biodegradable mixed polymeric micelles for drug delivery |
| 06/25/2002 | US6410056 Polylactide-glycolide copolymer |
| 06/25/2002 | US6410055 Spherical pharmaceutical granules comprising microcrystalline cellulose and a process for their production |
| 06/25/2002 | US6410054 Immediate release eplerenone compositions |
| 06/25/2002 | US6410053 Reversible cross-linked gel |
| 06/25/2002 | US6410052 Tea catechins in sustained release formulations as cancer specific proliferation inhibitors |
| 06/25/2002 | US6410050 Cellulose capsule using mixed solution of pectin and glycerin and the manufacturing process thereof |
| 06/25/2002 | US6410049 Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery |
| 06/25/2002 | US6410048 Prolamin-plant polar lipid combination, preparation method and applications |
| 06/25/2002 | US6410046 Administering pharmaceuticals to the mammalian central nervous system |
| 06/25/2002 | US6410045 Drug delivery system for antiglaucomatous medication |
| 06/25/2002 | US6410044 Crosslinkable macromers |
| 06/25/2002 | US6410039 Wet wipe comprising sheet wetted with emulsion including water, silicone oil, at least two nonionic surfactants to emulsify substantially all of silicone oil in water, synergistic blend of at least two water soluble preservatives |
| 06/25/2002 | US6410038 Multiple emulsion including water phase dispersed in oil first continuous phase of primary emulsion by crosslinked polyether containing silicone elastomer emulsifier, that emulsion being dispersed in second continuous nonaqueous polar solvent phase |
| 06/25/2002 | US6410036 Liquid, substantially anhydrous eutectic mixture comprising principal acid component and another component selected from carbohydrates, polyols, carbonylic compounds, amino acids and carboxylic acids |
| 06/25/2002 | US6410034 Agent consisting essentially of p-menthane-3,8-diol and 3-l-menthoxypropane-1,2-diol |
| 06/25/2002 | US6410023 Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene |
| 06/25/2002 | US6410019 Topical administration of immunoglobulins brings about remission of inflammatory process without causing any toxic or unwanted side effects |
| 06/25/2002 | US6410011 Treatment of restenosis by gene therapy, comprising the administration of a recombinant adenovirus containing a suicide gene |
| 06/25/2002 | US6410010 Recombinant P53 adenovirus compositions |
| 06/25/2002 | US6410006 Ophthalmic composition for keratoconjunctivitis sicca (dry eye) |
| 06/25/2002 | US6409992 Compositions to control oral microbial oxidation-reduction (Eh) levels |
| 06/25/2002 | US6409716 Drug delivery |
| 06/25/2002 | US6408854 Insulin delivery enhanced by coached breathing |
| 06/25/2002 | CA2234847C Formulation for respiratory tract administration |
| 06/25/2002 | CA2215210C Polyphenol fractions of tea, the use thereof and formulations containing them |
| 06/25/2002 | CA2140281C Analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis |
| 06/25/2002 | CA2101245C Dosage forms comprising polymers comprising different molecular weights |
| 06/25/2002 | CA2099586C Drug material suitable for micronisation |
| 06/22/2002 | CA2365812A1 Method and apparatus for forming composite pellets |
| 06/21/2002 | CA2366327A1 Personal medication dispensing card |
| 06/20/2002 | WO2002048380A2 Glycosilated cationic lipids for liposomes used in drug delivery |
| 06/20/2002 | WO2002048359A1 Magnetic particle membrane-specific protein |
| 06/20/2002 | WO2002048199A2 Production of carrageenan and carrageenan products |
| 06/20/2002 | WO2002048170A1 Lipids comprising an aminoxy group |
| 06/20/2002 | WO2002048142A1 Medicinal compositions having improved absorbability |
| 06/20/2002 | WO2002048141A1 Medicinal compositions improved in solublity in water |
| 06/20/2002 | WO2002048110A2 Composition for regulating animal growth, method of manufacture and use thereof |
| 06/20/2002 | WO2002047829A1 Surface modification process |
| 06/20/2002 | WO2002047731A2 Drug delivery compositions and coated medical devices |
| 06/20/2002 | WO2002047729A2 Drug delivery system comprising a drug intercalated between a layered double hidroxide |
| 06/20/2002 | WO2002047726A2 Pharmaceutical composition containing an active with a hemolytic action and a surfactant |
| 06/20/2002 | WO2002047725A2 Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same |
| 06/20/2002 | WO2002047723A1 Medicinal compositions having improved water-solubility |
| 06/20/2002 | WO2002047722A1 Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof |
| 06/20/2002 | WO2002047704A1 Herbal pharmaceutical compositions for treating immunological disorders |
| 06/20/2002 | WO2002047698A1 Remedies for dermatophytosis |
| 06/20/2002 | WO2002047694A1 Pharmaceutical compositions for treatment of digestive disorders and associated diseases |
| 06/20/2002 | WO2002047693A2 Steroid hormone products comprising a stabilizing agent in non-crystalline form |
| 06/20/2002 | WO2002047692A1 Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginitis |
| 06/20/2002 | WO2002047688A2 Method and apparatus for treating breakthrough pain |
| 06/20/2002 | WO2002047685A2 Nmda receptor agonist pharmaceutical compositions |
| 06/20/2002 | WO2002047676A1 Topical composition and method for treating urinary stress incontinence |
| 06/20/2002 | WO2002047674A2 Use of intracellular calcium chelators (e.g bapta-am) to increase surfactant secretion in the lungs |
| 06/20/2002 | WO2002047668A2 Novel medicament compositions based on anticholinesterase drugs and on ciclesonides |
| 06/20/2002 | WO2002047667A2 Novel medicament compositions based on anticholinesterase drugs and on a steroid |
| 06/20/2002 | WO2002047666A1 Use of a dopamine agonist with a short half-life for treating illnesses which can be treated by dopaminergic means |
| 06/20/2002 | WO2002047665A2 Methods and compositions for encapsulating active agents |
| 06/20/2002 | WO2002047664A2 Microparticles with an improved release profile and method for the production thereof |
| 06/20/2002 | WO2002047663A1 Self emulsifying lipid matrix (selm) |
| 06/20/2002 | WO2002047662A2 Antibiotic/benzoyl peroxide dispenser |
| 06/20/2002 | WO2002047661A1 Pharmaceutical composition for intramuscular injection containing loxoprofen |
| 06/20/2002 | WO2002047660A1 Pharmaceutical dronedarone composition for parenteral administration |
| 06/20/2002 | WO2002047659A2 Preparation of drug particles using evaporation precipitation into aqueous solutions |
| 06/20/2002 | WO2002047643A1 Water-free skin care formulations comprising micronized urea and method of manufacturing the same |
| 06/20/2002 | WO2002047615A2 Oral compositions and use thereof |
| 06/20/2002 | WO2002047607A2 Process for the preparation of a fast dissolving dosage form |
| 06/20/2002 | WO2002047492A2 A moisture and oxygen stable composition and a process for obtaining said composition |
| 06/20/2002 | WO2002028365A3 Stabilization of solid drug formulations |
| 06/20/2002 | WO2002013869A3 Flavone-containing plant extract solutions having improved storage and heat stability |
| 06/20/2002 | WO2002011669A3 Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof |
| 06/20/2002 | WO2002005800A8 Compositions for sustained release of analgesic agents, and methods of making and using the same |
| 06/20/2002 | WO2002002145A3 Composition for aqueous stabilization of fat-soluble vitamins |
| 06/20/2002 | WO2002002085A3 Rapidly-decomposing administrable form for releasing active ingredients in the oral cavity or in bodily cavities |
| 06/20/2002 | WO2001097780A3 Pharmaceutical compositions comprising an opioid analgesic |
| 06/20/2002 | WO2001097774A3 Novel pharmaceutical composition for the topical application of water-insoluble and/or hardly water-soluble active agents |
| 06/20/2002 | WO2001095933A3 Immunization through oral administration of a vaccine with an edible product |
| 06/20/2002 | WO2001087264A3 Rapidly disintegrating solid oral dosage form |
| 06/20/2002 | WO2001080825A3 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| 06/20/2002 | WO2001057064A3 Cationic amphiphiles for use in nucleic acid transfection |